Generate Biomedicines, Inc.
15.52USD
-0.3800 (-2.39%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-0.55▼ | $-0.54 | 1 | 2 |
| Next quarter | $-0.57▼ | $-0.55 | 1 | 2 |
| Current year | $-2.3▼ | $-2.24 | 2 | 2 |
| Next year | $-2.28▼ | $-2.07 | 0 | 2 |
Beat in 0 of the last 2
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-0.49 | $-0.52 | -0.03 (-5.6%) |
| 2026-03-31 | $-0.51 | $-1.07 | -0.56 (-111.2%) |
10 ratings from 6 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Reiterated | Buy | $30 | Sep 8, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $25 $30 | Aug 28, 2026 |
| Morgan Stanley | Maintained | Overweight | $20 $22 | May 14, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $16 $25 | May 8, 2026 |
| HC Wainwright & Co. | Initiated | Buy | $16 | Apr 13, 2026 |
| Goldman Sachs | Initiated | Buy | $26 | Mar 24, 2026 |
| Morgan Stanley | Initiated | Overweight | $20 | Mar 24, 2026 |
| Piper Sandler | Initiated | Overweight | $24 | Mar 24, 2026 |
| Cantor Fitzgerald | Initiated | Overweight | — | Mar 24, 2026 |
| Guggenheim | Initiated | Buy | $30 | Mar 24, 2026 |
9 filings from 7 insiders · 0 buy / 0 sell over 6m
Officers and directors of GENB, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| ARNOLD FRANCESDirector | Sell | 1.0k | $16.00 | $16k | Sep 1, 2026 |
| NALLY MICHAELChief Executive Officer | Buy | 20.0k | $12.00 | $240k | Mar 4, 2026 |
| NALLY MICHAELChief Executive Officer | Otherindirect | 658.3k | — | — | Mar 2, 2026 |
| BANCEL STEPHANE JDirector | Otherindirect | 724.2k | — | — | Mar 2, 2026 |
| AFEYAN NOUBAR BOGHOSDirector and Beneficial Owner of more than 10% of a Class of Security | Otherindirect | 32.97M | — | — | Mar 2, 2026 |
| GROUS BETHOfficer | Buyindirect | 300 | $16.00 | $5k | Mar 2, 2026 |
| SILVERS JASON M.D., J.D.President | Buyindirect | 2.0k | $16.00 | $32k | Mar 2, 2026 |
| MENDILLO JANE L.Director | Buy | 1.5k | $16.00 | $24k | Mar 2, 2026 |
| AFEYAN NOUBAR BOGHOSDirector and Beneficial Owner of more than 10% of a Class of Security | Buyindirect | 4.69M | $12.17 | $57.05M | Mar 2, 2026 |
No analyst notes on GENB yet.
Analyst Ratings
5 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 4 | 0 | 0 | 0 | Buy1.67 |
| 1 mo ago | 2 | 4 | 0 | 0 | 0 | Buy1.67 |